Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
5
×
boston blog main
clinical trials
life sciences
national blog main
boston top stories
dyne therapeutics
fda
myotonic dystrophy type 1
national top stories
new york blog main
rare disease drugs
san diego blog main
san francisco blog main
akouos
ally bridge group
astellas pharma
astellas pharmaceuticals
atlas venture
audentes therapeutics
avidity biosciences
big data analytics
biotech ipos
blackrock
bluebird bio
california institute for biomedical research
cancer
casdin capital
codiak biosciences
cutaneous t-cell lymphoma
deals
decibel therapeutics
diabetic nephropathy
duchenne muscular dystrophy
eventide asset management
exosome
facioscapulohumeral muscular dystrophy
focal segmental glomerulosclerosis
frequency therapeutics
What
ipo
5
×
medicines
5
×
drug
genetic
million
therapeutics
brings
company
developing
diseases
dyne
muscle
new
raised
rare
affects
ago
americans
analysis
approved
based
begin
bio
biosciences
biotech
biotechs
bio’s
bring
bubbles
cells
class
clinical
codiak
considering
data
date
develop
disorders
dyne’s
early
Language
unset
Current search:
boston
×
medicines
×
ipo
×
@xconomy.com
3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
